Your gut may predict inflammaging better than your birthday.

Not a probiotic ad. Nature Communications — DanFunD cohort, 1,199 adults aged 20–72.

Paired fecal microbiota + 30 plasma cytokines + physiology.

The punchline:
🟢 microbiota explained more variance than age for 97% of cytokines
🟢 and 84% of physiological measures
🟣 Bacteroides 2 enterotype: inflammaging-like profile up to ~37 years earlier
🟣 same pattern → higher future disease risk (HR ~1.21)
🟢 high-diversity enterotype → lower inflammation, lower risk

Caveats:
🟠 association, not a probiotic prescription
🟠 enterotypes are messy labels
🟠 Denmark cohort — not “your stool test = destiny”

🗒 Chronological age is a weak proxy for inflammatory tone. Your microbial community may be a louder — and more modifiable — signal.

Baseline while science catches up → https://t.me/AgePilotBot?start=ref_134163805

Source: Eriksen et al., Nature Communications, 8 Sep 2026

Cut the calories — and the genome takes fewer hits.

Not a longevity influencer tip. Cell, online now (9 Sep 2026).

Mice at −30% calories. High-fidelity duplex sequencing across liver, kidney, hepatocytes, cerebellar neurons.

What moved:
🟢 fewer substitutions genome-wide
🟢 fewer insertions/deletions
🟢 SBS5 — the quiet mutational process behind most mammalian mutations — dialed down
🟣 strongest drop in transcriptionally quiet DNA
🟣 liver felt it more than kidney or brain

Why it matters:
🟠 genomic instability is a hallmark of aging — diet just touched it
🟠 this is mice, not your intermittent-fasting protocol
🟠 extreme CR is hard and risky in humans — the goal is the mechanism, not the starvation

🗒 Lifespan links to diet were old news. Genome-wide mutation load as a modifiable aging axis is the new punchline.

Source: Grońska-Pęski, Evrony et al., Cell 2026 · DOI 10.1016/j.cell.2026.08.013

Ozempic’s cousin just bought old mice ~100 extra days.

Not a weight-loss ad. Nature (2 Sep 2026) — UC Berkeley / NIA: late-life semaglutide in healthy female mice.

Setup:
🟢 start at 20 months (~human 60s)
🟢 daily GLP-1RA until death → median lifespan ≈ +100 days (~12%)
🟣 vs matched 24% calorie restriction: drug kept memory, curiosity, and blood sugar better
🟣 metabolic rate stayed up — CR slowed it down

Why it’s juicy:
🟠 looks like a CR mimetic… plus extras that aren’t “just eat less”
🟠 hallmarks dialed down: inflammation, weak regeneration
🟠 female mice only — no human longevity claim yet

🗒 This morning: CR cut genome mutations. This afternoon: a GLP-1RA stretches late life in mice. Same axis, different tool.

TellMeGen — DNA context for the habits you keep stacking.

Source: Feng, Chen et al., Nature 2026 · DOI 10.1038/s41586-026-10940-7

Senescent cells wear an immune cloak — and it has a name: PD-L2.

Cell Metabolism (online today, 10 Sep 2026) — Cedars-Sinai / Kirkland lab.

What’s new:
🟢 PD-L2 rises on senescent cells and with aging
🟢 soluble PD-L2 climbs in blood; senolytics can knock the high-PD-L2 cells down in humans
🟢 PD-L2 knockout mice keep fewer zombies — better insulin sensitivity + grip strength
🟣 anti-PD-L2 restored insulin sensitivity in old wild-type mice

Why it bites:
🟠 senescent cells aren’t just “stuck” — they may actively hide from clearance
🟠 this is still mostly mouse + biomarker evidence, not a clinic drug
🟠 checkpoint blockade has real immune risks — don’t DIY oncology tools for longevity

🗒 Senolytics kill. Immune surveillance unmasks. PD-L2 sits at that intersection.

Source: Chaib, Kirkland et al., Cell Metabolism 2026 · DOI 10.1016/j.cmet.2026.08.014

Six aging clocks. One AI-designed drug. Younger blood proteomes.

Nature Biotechnology (7 Sep 2026) — Phase 2a rentosertib (Insilico), the generative-AI TNIK inhibitor for IPF.

What moved:
🟢 six independent proteomic aging clocks all trended younger on drug vs placebo
🟢 peak ~3–4 years younger at week 4 (30 mg BID); up to ~6 on one clock
🟢 FVC improved too — but best lung dose ≠ strongest clock signal
🟣 senomorphic shift: less senescence/fibrosis proteins, remapped growth-factor paths

Caveats:
🟠 n=42, company-sponsored, exploratory biomarkers — not a lifespan trial
🟠 clocks can’t fully untangle less fibrosis from slower aging
🟠 don’t DIY an IPF investigational for “bio-age”

🗒 Put aging endpoints inside disease trials — geroprotection may show up years earlier.

AgePilot — habits that move the healthspan dial.

Source: Zhavoronkov et al., Nat Biotechnol 2026 · DOI 10.1038/s41587-026-03286-y

Turn off growth-hormone signaling at midlife — mice live longer.

Aging Cell (5 Sep 2026) — Duran-Ortiz / Kopchick: inducible Ghr knockout at 12 months (roughly human midlife). Not a lifelong dwarf model.

What moved:
🟢 lifespan up in both sexes (log-rank: ♂ p=0.0085, ♀ p=0.0264)
🟢 females: ~8% median (1003 vs 929 days); max lifespan +12%
🟢 males: ~7% median trend; better insulin sensitivity + preserved bone/strength signals
🟣 classic GH resistance: lower IGF-1, higher GH — without wrecking adult growth

Caveats:
🟠 mice + genetic KO, not a human drug trial
🟠 more fat / less lean later — weird body-comp tradeoff
🟠 total GH block ≠ safe DIY; FDA-approved antagonist pegvisomant still untested for aging

🗒 Congenital GH/IGF-1 cuts already win longevity contests. This paper asks the clinic-relevant question: is midlife late enough — and answers yes, in mice.

Source: Duran-Ortiz et al., Aging Cell 2026 · DOI 10.1111/acel.70695

Why is human longevity still a billionaire blind spot?

NFX Bio / Longevity.Technology: science is at an inflection — reprogramming, organs, delivery, AI discovery, diagnostics. Tech tree mapped. Capital is not.

Aging is the #1 disease risk factor, yet under 0.5% of NIH funding. Many ultra-wealthy stay away: burned by clinics, doubt aging is fixable, assume wealth buys the cure later, or fear looking vain.

🟢 New (year to 2026):
• Healthspan VC ~2.3x in 2025 — SVB: mostly a few megadeals
• Flagships dominate: Altos, Retro, NewLimit
• 2026: Life Biosciences ER-100 (partial OSK) entered human dosing
• Calico fosigotifator fail (2025) + AbbVie exit — big checks ≠ proof

Caveat: money is concentrated, not absent. Missing: a broad pipeline through failure, biomarkers, human outcomes.

Longevity.Technology

DNA risk map → TellMeGen

Your organs don’t age as one clock — and the immune system may lead the pack.

Nature Communications (9 Sep 2026) — plasma proteomes from 53,014 UK Biobank people → 16 organ/system aging clocks. Validated in China Kadoorie Biobank (n=3,977).

What jumped out:
🟢 5,436 links to 1,059 diseases — organ-specific and pan-organ patterns
🟢 clocks react across 841 environmental factors
🟢 genetics: 261 loci; immune + liver are the most connected hubs
🟣 longitudinal network (n=1,006): immune, liver, stomach show temporal precedence (artery stronger in ♀, stomach in ♂)

Caveats:
🟠 clocks from blood proteins — not a biopsy of every organ
🟠 “precedence” is statistical, not proof of causation
🟠 atlas ≠ a therapy you can take tonight

🗒 Aging is a network of organs, not one birthday. The next geroprotectors may need organ-level targets — not just “biological age.”

Source: Nat Commun 2026 · DOI 10.1038/s41467-026-77365-8

Danshen's phenolic acids just cleared zombie cells — and old mice lived longer.

npj Aging (11 Sep 2026) — Zhang / Sun / Kirkland: salvianolic acids A, B, E from Salvia miltiorrhiza, screened from 55 natural agents.

What's new:
🟢 selective kill of senescent cells across lineages
🟢 hit GSTP1 (redox shield) → ROS surge → apoptosis + ferroptosis
🟢 biweekly SAA from 24–27 mo (~human 75–90): +51% median remaining life / +11% overall lifespan; mortality hazard −68%
🟣 better grip, walking, endurance — without a longer sick stretch at the end

Caveats:
🟠 mice + intermittent i.p. — not your herbal tea
🟠 oral bioavailability of SAs is notoriously poor
🟠 still needs independent replication before hype

🗒 Late-life senolysis that works when started “old” is the rare punchline. Danshen capsules ≠ this protocol.

AgePilot — habits that move the healthspan dial → t.me/AgePilotBot

Source: Zhang et al., npj Aging 2026 · DOI 10.1038/s41514-026-00496-1

Your voice just became a biological clock — in 30 seconds.

npj Aging (11 Sep 2026) — Krongauz / Segal: “Voice Age” from a short speech clip in 6,979 adults (40–70, Hebrew-speaking).

What's new:
🟢 sex-stratified models on WavLM-Large embeddings
🟢 women: R² 53.9%, MAE ~4.0 y · men: R² 44.0%, MAE ~4.4 y
🟢 #2 of 9 single-modality age models — only partly overlaps DNA/imaging/lifestyle clocks
🟣 stacking Voice Age onto other clocks always helped; + metabolomics → R² up to 65% (♀)
🟣 “Voice Age acceleration” tracked adiposity, sleep apnea signals, liver imaging

Caveats:
🟠 one language / one country / ages 40–70
🟠 predicts chronological age well — not yet proven as an intervention endpoint
🟠 mic quality, accent, illness can shift the score

🗒 Longevity needs cheap, frequent readouts. If a phone clip carries independent aging signal, that’s a new sensor class — not a magic mirror.

Source: Krongauz et al., npj Aging 2026 · DOI 10.1038/s41514-026-00519-x

There’s a chance to minimize the catastrophe.

Amodei’s We Must Pace the Frontier: not a halt — a brake so safety keeps up. Longevity upside depends on it.

AI can crush drug discovery, aging clocks, personalized medicine. Lose a decade to a misaligned swarm or panic politics — and that upside slips.

🟢 RSI already speeds model→model progress
🟢 HF swarm = warning (Dario: 6–12 mo to catastrophic cyber scale if we keep racing)
🟢 Asks: embedded independent evaluators · pre-release gates · democratic coordination

Can’t stop progress. Can refuse reckless release.

Essay

DNA risk map → TellMeGen

Which aging clocks actually move when you intervene?

Nature Medicine — Sehgal / Higgins-Chen (Yale + TruDiagnostic): TranslAGE harmonizes 51 human longevity trials and scores the same 16 epigenetic clocks (+94 other DNAm markers) on every study.

What's new:
🟢 mortality / pace clocks (esp. DunedinPACE, PCGrimAge) respond most — not Horvath-style chrono clocks
🟢 pharma + lifestyle beat supplements / procedures on average
🟢 anti-TNF + Mediterranean diet: most reproducible across studies
🟢 senolytic epigenetic signals look inconsistent study-to-study
🟢 bigger shifts in disease cohorts than healthy ones

Caveat: clock movement ≠ proven healthspan or lifespan gain. Responsiveness is a prerequisite for surrogate endpoints — not the surrogate itself.

🗒 Takeaway: for trial design, prioritize reliable Gen2+ clocks — and match the clock to the intervention class.

APOE4 doesn't just float amyloid — it floods the blood–brain barrier with fibronectin.

Nature Aging (11 Sep 2026) — Columbia: why ε4 carriers get early BBB leak — and how rare FN1 protection may blunt it (~71% lower AD risk in prior genetics).

What's new:
🟢 astrocytes dump excess fibronectin (FN1) around vessels under APOE4 + Aβ42 + inflammation
🟢 FN1 alone is enough to break the barrier (integrin → FAK → VEGF / HB-EGF / IGF-1 collapses)
🟢 APOE4 mice: ~2× brain fibronectin vs APOE3 + leaky barrier
🟢 cut FN1 or restore growth-factor signaling → BBB returns (cells, fish, mice)
🟣 human brains + CSF: high FN1 tracks inflamed astrocytes

Caveats:
🟠 mechanism paper — not a drug trial
🟠 FN1 also heals wounds; blanket blockade could bite

🗒 Brain aging may be as much vascular-interface as plaque — FN1 is now a concrete dial.

AgePilot — habits that move healthspan → t.me/AgePilotBot

Senescent cells need mitochondrial citrate to scream inflammation — cut the export, quiet the SASP.

Nature — Martini et al.: zombie cells keep the cycle-arrest program, but their inflammatory shout runs on a metabolic–epigenetic checkpoint.

What's new:
🟢 senescent cells ramp the pyruvate → citrate → acetyl-CoA axis
🟢 SLC25A1 exports citrate; ACLY makes acetyl-CoA for histone marks at SASP genes
🟢 mtDNA / cGAS–STING lights the fuse — acetyl-CoA lets transcription actually fire
🟢 CTPI2 (SLC25A1 block): SASP down, p16/p21 arrest stays
🟢 aged mice: less SASP chromatin access, less inflammation, delayed frailty, better strength

Caveats:
🟠 mice + cells — not a human trial
🟠 senomorphic (mute the shout), not senolytic (kill the cell)

🗒 You may not need to erase every senescent cell — starve the inflammatory license instead.

Calorie cuts move aging blood markers — and not just because you weigh less.

GeroScience (12 Sep 2026) — Guida et al. pooled 7 randomized CR trials in older adults (n = 829). Composite index: CRP, IL-6, cystatin C, insulin, GDF-15, TNF-R1.

What's new:
🟢 CR improved the composite vs control (−2.2 quintile-change score)
🟢 strongest shifts: inflammation + insulin signaling (CRP, IL-6, insulin, TNF-R1)
🟣 weight loss explained only ~48.5% of the CR effect — the rest looks energy-balance biology, not just the scale
🟢 still significant after adjusting for weight (−1.2)

Caveats:
🟠 short-term trials — not a lifespan RCT
🟠 composite ≠ epigenetic clock; markers can move without proving more years

🗒 Human CR isn’t only thinner — a TAME-style blood panel actually shifts.

DNA aging risk check → TellMeGen

One gut microbe keeps vanishing with age — and its metabolite may be the geroprotective signal.

Nature Aging (25 Aug 2026) — CAS / CNCB: Bifidobacterium pseudocatenulatum + 5-AVAB, tracked with a new microbiome clock (MicroAge).

What's new:
🟢 BP depletes with aging across sexes and Chinese cohorts
🟢 higher BP → younger MicroAge vs clinical health markers
🟢 oral BP in old mice: gut homeostasis ↑, multiorgan inflammaging ↓, cognition/motor ↑, healthspan ↑
🟢 key metabolite 5-aminovaleric acid betaine (5-AVAB) also falls in aging humans
🟣 5-AVAB alone partly copies the benefits (memory, motor, inflammation)

Caveats:
🟠 mouse intervention + human observational layers — not a human probiotic trial yet
🟠 species/strain and dose still open questions

🗒 Inflammaging may have a microbial dial: restore the bug — or its molecule.

Chronic inflammation in aging may start in your blood stem cells — and SIRT3 is the brake.

Nature Aging (16 Jul 2026) — UC Berkeley / Buck / Netea: SIRT3 in hematopoietic stem cells (HSCs) suppresses maladaptive trained immunity.

What's new:
🟢 SIRT3 is high in HSCs and falls with age (mice + humans)
🟢 Without that brake, HSCs launch epigenetic inflammatory training → myeloid-biased progeny → chronic inflammation
🟢 HSC SIRT3 overexpression: lower TNF/IL-6, fewer tissue macrophages, better muscle, cognition, glucose, lung structure in old mice
🟣 Benefits travel via myeloid cells — not just “fixing the bone marrow”

Caveats:
🟠 mouse genetics / transplants — not a human SIRT3 drug trial yet
🟠 how mitochondria rewrite chromatin in HSCs still partly open

🗒 Inflammaging may be written in stem-cell memory. Target the HSC program, not only the cytokine.

AgePilot — habits that move healthspan → t.me/AgePilotBot

An FDA leukemia drug just cleared senescent fat cells — and stretched mouse lifespan.

Nature Communications — screen of 2,150 clinical compounds. Hit: homoharringtonine (HHT) / omacetaxine.

What's new:
🟢 senolytic on human preadipocytes + other senescent cell types; spares non-senescent cells
🟢 HF obese + aged mice: less WAT senescence, better insulin sensitivity, healthier adipose remodeling
🟢 human WAT explants: SAβG / p53 / p21 down
🟣 mechanism: binds HSPA5 (GRP78), blocks ATPase → kills HSPA5-high senescent cells
🟢 lifespan ↑ in progeroid (Zmpste24−/−) and aged / HF-aged mice

Caveats:
🟠 mice + ex vivo human fat — not a human longevity trial
🟠 oncology drug: aging dose/schedule still unknown
🟠 mostly male mice; anti-cancer vs senolytic split still open

🗒 Sometimes the next senolytic is already on the shelf — with a new target (HSPA5) attached.

Japan has 107,600 centenarians now — but the real question is not lifespan. It’s healthspan.

Almost 90% are women.

That sounds impressive.
But the number that matters is not how many people reach 100.

It’s this:

How do they live their last 20 years?

Because longevity without healthspan means:
• frailty
• disability
• dependence
• dementia
• exploding care costs

So Japan is not just testing how long humans can live.

It is testing whether modern society can support millions of very old people living very differently from one another — some active, some bedridden, some cognitively sharp, some not.

That is the real future every aging country is walking into.

🧬 And if you want facts instead of guesswork, you can check your sex through a DNA test — and unlock 1000+ parameters about your body. Use my link for complete DNA sequencing: https://shop.tellmegen.com/en?sca_ref=11848100.IoSIJUJzfNYC4

A sugar-pathway molecule just showed up as an inflammaging brake.

Nature Aging — Song / Hu / Li: phosphoenolpyruvate (PEP), a glycolytic metabolite, as an endogenous cGAS inhibitor.

What's new:
🟢 mice + humans: PEP rises early in aging, then falls — a biphasic “protect then fade” curve
🟢 block PEP buildup → more inflammation, faster aging traits
🟢 give PEP before the decline → healthier aging in mice
🟢 aged humans with higher PEP → lower inflammation + healthier traits
🟣 mechanism: PEP competitively binds cGAS → dials down cGAS–STING
🟢 AD mice: less neuroinflammation, better cognition

Caveats:
🟠 mice intervention + human correlation — not a human PEP pill trial
🟠 timing matters: benefit shown before the late decline window
🟠 don’t confuse this with “more sugar = longevity”

🗒 Inflammaging isn’t only cytokines. A metabolite can sit on the cGAS switch.

DNA context for the habits you keep stacking → TellMeGen

Source: Song et al., Nature Aging 2026 · DOI 10.1038/s43587-026-01087-1

Your brain has a second proteome — and Alzheimer’s rearranges it.

Nature Aging (14 Sep 2026) — Salk / Miller + Saghatelian: first microprotein atlas of the human frontal cortex (AD vs non-AD).

What's new:
🟢 >600 postmortem cortices → transcriptomics + mass spec + deep-learning spectra
🟢 1,067 microproteins (≤150 aa) missing from reviewed UniProt — high-confidence spectral support
🟢 a subset shifts in AD independently of the main ORF at the same locus
🟣 Micro-MKKS63 (63 aa at the MKKS locus): the predominant translation product there, downregulated in AD
🟣 knock it out in microglia → mitochondrial respiration collapses

Caveats:
🟠 atlas + mechanism clue — not a drug
🟠 postmortem human tissue; Micro-MKKS63 is one hit among >1,000
🟠 “new proteins” ≠ instant targets — validation still ahead

🗒 Aging and neurodegeneration may have been missing a whole protein class. Microproteins just joined the map.

Source: Miller et al., Nature Aging 2026 · DOI 10.1038/s43587-026-01207-x